Identification of New Molecular Targets and Innovative Systems for Diagnosis and Therapy of human diseases: GEAR has developed numerous experimental systems to identify and validate molecules to be studied as candidate drugs for human diseases. Genomic and proteomic analyses have been developed for the identification of markers for diagnosis and disease monitoring. HTS equipments and suitable assays are available.

Services for Molecular Diagnosis and Functional Genomics: It is the result of the development of high throughput instruments and strategies for the analysis of genomic and proteomic information in the medical field. In addition to supplying advanced diagnostic services it can be useful for preparing prototype kits for molecular diagnostics. The high throughput systems, from gene sequencing to proteomic analysis together with the bioinformatics facility, are an useful instrument for obtaining information on the molecular mechanisms at the basis of the pathological situations vital for identifying specific diagnostic targets and developing new kits. This service’s innovation lies in its capacity to make new molecular techniques available for diagnostics and also for those who can develop new therapeutic approaches.

Murine Models of Human Pathologies for Preclinical Evaluation of Innovative Therapeutic Protocols: GEAR can manage murine models and, through the genomic and proteomic platforms conduct preclinical studies on new therapeutic treatments particularly in areas where there is a consolidated knowledge (e.g. tumours of the thyroid). The Centre has the capacity to generate, manage and study genetically modified animals. Its expertise is fundamental for the development of commercial products that can be used by companies in the biomedical sector.

GEAR avails of a network of highly specialized laboratories, in the Campania Region, organized in four sections: discovery and analysis of pharmaceutical substances, development of diagnostic instrumentation, management of discoveries and inventions, development of new technology. The Centre’s principal competitive advantages lie in the scientific excellence of its work, proven by the high number of domestic and international collaborations and projects carried out and underway, and by the direct link with clinical fields in which research and development work is being carried out for some time. The Centre’s expertise, quality, know-how and technology are available to industrial partners who have the possibility of utilizing this instrumentation and these services to develop new diagnostic products.

The Centre is aimed at companies who seek highly qualified consultancy and services in innovative product and process development, public and private enterprises which perform research and development work in human healthcare and promote collaborations in R&D work.

Pharma e Biotech Companies